Aquestive Therapeutics (AQST) Issues Earnings Results, Beats Expectations By $0.35 EPS

Aquestive Therapeutics (NASDAQ:AQST) announced its earnings results on Thursday. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.35, MarketWatch Earnings reports. The business had revenue of $16.82 million for the quarter, compared to analyst estimates of $17.05 million. Aquestive Therapeutics updated its FY 2019 guidance to EPS.

Shares of AQST stock traded up $0.17 on Friday, hitting $6.54. The stock had a trading volume of 600 shares, compared to its average volume of 114,662. The company has a debt-to-equity ratio of 1.88, a quick ratio of 3.42 and a current ratio of 3.63. Aquestive Therapeutics has a 52-week low of $5.60 and a 52-week high of $20.70.

Several hedge funds have recently made changes to their positions in AQST. Geode Capital Management LLC grew its holdings in Aquestive Therapeutics by 77.6% in the 4th quarter. Geode Capital Management LLC now owns 44,208 shares of the company’s stock valued at $278,000 after buying an additional 19,310 shares in the last quarter. Millennium Management LLC bought a new position in Aquestive Therapeutics in the 4th quarter valued at about $145,000. Squarepoint Ops LLC bought a new position in Aquestive Therapeutics in the 4th quarter valued at about $188,000. Perceptive Advisors LLC grew its position in Aquestive Therapeutics by 83.8% in the 4th quarter. Perceptive Advisors LLC now owns 2,113,400 shares of the company’s stock valued at $13,314,000 after buying an additional 963,400 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new position in Aquestive Therapeutics in the 4th quarter valued at about $108,000. Institutional investors and hedge funds own 58.34% of the company’s stock.

Several research firms have issued reports on AQST. Lake Street Capital began coverage on shares of Aquestive Therapeutics in a research note on Thursday, January 3rd. They set a “buy” rating and a $14.00 price objective for the company. Wedbush set a $30.00 price objective on shares of Aquestive Therapeutics and gave the stock a “buy aqst” rating in a research note on Thursday, December 20th. Finally, Zacks Investment Research downgraded shares of Aquestive Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, November 20th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $23.60.

COPYRIGHT VIOLATION NOTICE: This news story was first published by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2019/03/15/aquestive-therapeutics-aqst-issues-earnings-results-beats-expectations-by-0-35-eps.html.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. Its products are developed using its PharmFilm technology. The company's marketed products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron antagonist for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery.

Read More: Sell-Side Analysts

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply